Prophylactic Vancomycin in the Primary Prevention of <i>Clostridium difficile</i> in Allogeneic Stem Cell Transplant
Prophylactic vancomycin was associated with a marked reduction in C. difficile infection in allogeneic transplant patients. Despite no significant impact on other clinical outcomes, there was a significant reduction in symptomatic C. difficile infection. Further prospective studies are warranted.
Authors
- Patricia Greenberg (ORCID: https://orcid.org/0000-0001-6652-5019)
- Roger Strair (ORCID: https://orcid.org/0000-0002-1881-7989)
- Nicole McEntee
- Anne Tyno
- Dale Schaar (ORCID: https://orcid.org/0000-0001-7627-548X)
- Dennis Cooper (ORCID: https://orcid.org/0000-0003-0233-8876)
- Brendon Fusco (ORCID: https://orcid.org/0000-0002-9707-721X)
- Jasmine Tomita‐Barber (ORCID: https://orcid.org/0000-0003-3214-4650)
- Natale Mazzaferro (ORCID: https://orcid.org/0000-0001-9365-9207)
Institutions
- Rutgers, The State University of New Jersey (US)
- Albert Einstein College of Medicine (US)
- Johnson University (US)
- Rutgers Cancer Institute (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1111/tid.70025
- Citations
- 1
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 1.40